Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy

Notified -

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia